Availability of Free Drug Provision for Patients with Type 2 Diabetes at the Outpatient Level in the Republic of Kazakhstan

IF 0.5 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Ethiopian Journal of Health Development Pub Date : 2022-01-01 DOI:10.32921/2225-9929-2022-2-46-4-12

Ansar Kablaev, Zh A Dauletkalieva, Sh. S. Kalieva

{"title":"Availability of Free Drug Provision for Patients with Type 2 Diabetes at the Outpatient Level in the Republic of Kazakhstan","authors":"Ansar Kablaev, Zh A Dauletkalieva, Sh. S. Kalieva","doi":"10.32921/2225-9929-2022-2-46-4-12","DOIUrl":null,"url":null,"abstract":"The purpose of the study: To analyze the availability of free drug provision for patients with type 2 diabetes at the outpatient level in the Republic of Kazakhstan.Methods: in this work, a comparative analysis of the drug provision of patients with type 2 diabetes mellitus was carried out within the framework of the list of outpatient drug provision and the clinical protocol for the treatment of type 2 diabetes mellitus. A pharmacoeconomic analysis was also carried out in terms of calculating the annual cost of pharmacotherapy with drugs for the treatment of type 2 diabetes mellitus.Results. 42 types of medicines are included in the clinical protocol for the treatment of type 2 diabetes mellitus, of which 24 international nonproprietary names for the treatment of type 2 diabetes are included in the List of free outpatient drug provision (6 oral combinations are also possible). Thus, patients with type 2 diabetes mellitus in the Republic of Kazakhstan have access to 71% of medicines from the clinical protocol for free drug provision.The cost of annual therapy with sitagliptin and alogpliptin is cheaper than analogues, and the results of efficacy and safety are comparable, the inclusion of these drugs in the list of free drug provision will also make it possible to make 2 oral combinations, which will increase the availability of free outpatient drug provision for patients with type 2 diabetes mellitus, and increase this show up to 81%.Conclusions. For patients with type 2 diabetes, 30 types of drugs are available for free outpatient drug provision, which is 71% of the drugs included in the clinical protocol.To increase accessibility, we consider it appropriate to include the drug alogliptin in the list of outpatient drug provision.Key words: type 2 diabetes mellitus, availability of drug provision, pharmacotherapy, of type 2 diabetes mellitus","PeriodicalId":11852,"journal":{"name":"Ethiopian Journal of Health Development","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ethiopian Journal of Health Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32921/2225-9929-2022-2-46-4-12","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of the study: To analyze the availability of free drug provision for patients with type 2 diabetes at the outpatient level in the Republic of Kazakhstan.Methods: in this work, a comparative analysis of the drug provision of patients with type 2 diabetes mellitus was carried out within the framework of the list of outpatient drug provision and the clinical protocol for the treatment of type 2 diabetes mellitus. A pharmacoeconomic analysis was also carried out in terms of calculating the annual cost of pharmacotherapy with drugs for the treatment of type 2 diabetes mellitus.Results. 42 types of medicines are included in the clinical protocol for the treatment of type 2 diabetes mellitus, of which 24 international nonproprietary names for the treatment of type 2 diabetes are included in the List of free outpatient drug provision (6 oral combinations are also possible). Thus, patients with type 2 diabetes mellitus in the Republic of Kazakhstan have access to 71% of medicines from the clinical protocol for free drug provision.The cost of annual therapy with sitagliptin and alogpliptin is cheaper than analogues, and the results of efficacy and safety are comparable, the inclusion of these drugs in the list of free drug provision will also make it possible to make 2 oral combinations, which will increase the availability of free outpatient drug provision for patients with type 2 diabetes mellitus, and increase this show up to 81%.Conclusions. For patients with type 2 diabetes, 30 types of drugs are available for free outpatient drug provision, which is 71% of the drugs included in the clinical protocol.To increase accessibility, we consider it appropriate to include the drug alogliptin in the list of outpatient drug provision.Key words: type 2 diabetes mellitus, availability of drug provision, pharmacotherapy, of type 2 diabetes mellitus

查看原文本刊更多论文

哈萨克斯坦共和国门诊2型糖尿病患者免费药物供应的可得性

本研究的目的:分析哈萨克斯坦共和国门诊2型糖尿病患者免费药物供应的可得性。方法:在门诊药物供应清单和2型糖尿病治疗临床方案的框架下，对2型糖尿病患者的药物供应情况进行对比分析。在计算治疗2型糖尿病的药物治疗的年度费用方面，还进行了药物经济学分析。治疗2型糖尿病的临床方案中包括42种药物，其中24种治疗2型糖尿病的国际非专利名称被列入免费门诊药物提供清单(6种口服组合也是可能的)。因此，哈萨克斯坦共和国2型糖尿病患者可以从免费提供药物的临床方案中获得71%的药物。西格列汀和阿格格列汀的年治疗费用比类似物更便宜，且疗效和安全性结果相当，将这两种药物纳入免费提供药物清单也将使2种口服联合用药成为可能，这将增加2型糖尿病患者门诊免费提供药物的可获得性，使其可获得性增加81%。对于2型糖尿病患者，门诊免费提供30种药物，占临床方案所含药物的71%。为了增加可及性，我们认为将药物阿格列汀列入门诊药物供应清单是适当的。关键词:2型糖尿病;药物供应可得性;药物治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ethiopian Journal of Health Development PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

0.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Ethiopian Journal of Health Development is a multi and interdisciplinary platform that provides space for public health experts in academics, policy and programs to share empirical evidence to contribute to health development agenda. We publish original research articles, reviews, brief communications and commentaries on public health issues, to inform current research, policy and practice in all areas of common interest to the scholars in the field of public health, social sciences and humanities, health practitioners and policy makers. The journal publishes material relevant to any aspect of public health from a wide range of fields: epidemiology, environmental health, health economics, reproductive health, behavioral sciences, nutrition, psychiatry, social pharmacy, medical anthropology, medical sociology, clinical psychology and wide arrays of social sciences and humanities. The journal publishes the following types of contribution: 1) Peer-reviewed original research articles and critical or analytical reviews in any area of social public health. These papers may be up to 3,500 words excluding abstract, tables, and references. Papers below this limit are preferred. 2) Peer-reviewed short reports of research findings on topical issues or published articles of between 2000 and 4000 words. 3) Brief communications, and commentaries debating on particular areas of focus, and published alongside, selected articles. 4) Special Issues bringing together collections of papers on a particular theme, and usually guest edited. 5) Editorial that flags critical issues of public health debate for policy, program and scientific consumption or further debate